Aim Immunotech Stock Current Liabilities
| AIM Stock | USD 0.23 0.02 9.52% |
AIM ImmunoTech fundamentals help investors to digest information that contributes to AIM ImmunoTech's financial success or failures. It also enables traders to predict the movement of AIM Stock. The fundamental analysis module provides a way to measure AIM ImmunoTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AIM ImmunoTech stock.
As of the 1st of December 2024, Total Current Liabilities is likely to grow to about 9.1 M, while Non Current Liabilities Total is likely to drop about 470.2 K. AIM | Current Liabilities |
AIM ImmunoTech Company Current Liabilities Analysis
AIM ImmunoTech's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current AIM ImmunoTech Current Liabilities | 6.65 M |
Most of AIM ImmunoTech's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AIM ImmunoTech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
AIM Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for AIM ImmunoTech is extremely important. It helps to project a fair market value of AIM Stock properly, considering its historical fundamentals such as Current Liabilities. Since AIM ImmunoTech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AIM ImmunoTech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AIM ImmunoTech's interrelated accounts and indicators.
Click cells to compare fundamentals
AIM Current Liabilities Historical Pattern
Today, most investors in AIM ImmunoTech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AIM ImmunoTech's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of AIM ImmunoTech current liabilities as a starting point in their analysis.
AIM ImmunoTech Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
AIM Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, AIM ImmunoTech has a Current Liabilities of 6.65 M. This is 99.62% lower than that of the Biotechnology sector and 98.78% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.92% higher than that of the company.
AIM Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AIM ImmunoTech's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AIM ImmunoTech could also be used in its relative valuation, which is a method of valuing AIM ImmunoTech by comparing valuation metrics of similar companies.AIM ImmunoTech is currently under evaluation in current liabilities category among its peers.
AIM Fundamentals
| Return On Equity | -1.55 | ||||
| Return On Asset | -0.8 | ||||
| Operating Margin | (73.88) % | ||||
| Current Valuation | 10.86 M | ||||
| Shares Outstanding | 63.71 M | ||||
| Shares Owned By Insiders | 8.57 % | ||||
| Shares Owned By Institutions | 14.07 % | ||||
| Number Of Shares Shorted | 491.37 K | ||||
| Price To Earning | 12.50 X | ||||
| Price To Book | 5.03 X | ||||
| Price To Sales | 72.93 X | ||||
| Revenue | 202 K | ||||
| Gross Profit | (715 K) | ||||
| EBITDA | (31.68 M) | ||||
| Net Income | (28.96 M) | ||||
| Cash And Equivalents | 27.05 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 718 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.21 X | ||||
| Book Value Per Share | 0.19 X | ||||
| Cash Flow From Operations | (21.27 M) | ||||
| Short Ratio | 1.63 X | ||||
| Earnings Per Share | (0.47) X | ||||
| Price To Earnings To Growth | (0.04) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 26 | ||||
| Beta | -0.36 | ||||
| Market Capitalization | 14.66 M | ||||
| Total Asset | 19.38 M | ||||
| Retained Earnings | (409.51 M) | ||||
| Working Capital | 34.96 M | ||||
| Current Asset | 15.73 M | ||||
| Current Liabilities | 6.65 M | ||||
| Net Asset | 19.38 M |
About AIM ImmunoTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AIM ImmunoTech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AIM ImmunoTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AIM ImmunoTech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out AIM ImmunoTech Piotroski F Score and AIM ImmunoTech Altman Z Score analysis. To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 0.004 | Quarterly Revenue Growth 0.19 | Return On Assets (0.80) | Return On Equity (1.55) |
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.